Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immutep Limited (IMMP) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Immutep submits current reports on Form 6-K under the Securities Exchange Act of 1934, furnishing investors with official information on clinical progress, regulatory interactions, collaborations and financial updates.
Recent Form 6-K filings include press releases on key milestones such as the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, translational and pathologic response data from the EFTISARC-NEO Phase II trial in soft tissue sarcoma, new data from the AIPAC-003 Phase II breast cancer study, and progress in the IMP761 Phase I program for autoimmune diseases. Other filings report on the successful completion of FDA Project Optimus requirements and agreement on the optimal biological dose for eftilagimod alfa, as well as R&D tax incentive payments from the French government and quarterly activities reports.
Through this page, users can follow how Immutep communicates material developments in its LAG-3–focused pipeline, including oncology and autoimmune programs, to the US market. Each 6-K typically incorporates an exhibit containing the full text of a company announcement, such as clinical trial updates, strategic collaborations like the exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected territories, or summaries of cash position and R&D spending.
Stock Titan enhances these filings with AI-powered tools that help readers quickly understand the significance of each document. Summaries highlight the core message of new 6-Ks, while structured views make it easier to compare successive disclosures about the same trial or program. Investors can use this page to stay aligned with Immutep’s official SEC record, track the evolution of its clinical and corporate strategy and reference historical filings for deeper due diligence on IMMP.
Immutep Limited reported a half-year loss after tax of A$44.86 million for the period ended 31 December 2025, compared with A$22.38 million a year earlier, as research and development and intellectual property expenses rose to A$46.62 million from A$25.33 million.
Total revenue and other income increased 6% to A$7.74 million, driven by A$4.08 million of license revenue from a strategic collaboration and licensing agreement with Dr. Reddy’s and A$1.93 million of grant income, partly offset by lower interest income and foreign exchange gains.
Net tangible assets per share fell to 6.31 cents from 11.30 cents, and net assets declined to A$98.90 million from A$143.64 million. Immutep ended the half-year with cash and short-term investments of approximately A$99.1 million, which was subsequently boosted by a US$20 million (A$29.9 million) upfront payment from Dr. Reddy’s, taking the pro-forma balance to A$129.3 million.
Operationally, the company advanced its lead immunotherapy eftilagimod alfa (efti) through the registrational TACTI-004 Phase III trial in first-line non-small cell lung cancer, reported encouraging data across multiple oncology trials, and progressed Phase I development of its autoimmune candidate IMP761 while a long-term vendor agreed to defer approximately A$30 million of future Biologics License Application readiness payments by up to 30 months.
Immutep Limited reported that it has reached 50% of the planned patient enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line advanced or metastatic non-small cell lung cancer. The study evaluates eftilagimod alfa (efti) combined with KEYTRUDA (pembrolizumab) and chemotherapy versus KEYTRUDA, chemotherapy and placebo.
The registrational trial has enrolled 378 patients worldwide and plans to enrol approximately 756 patients across more than 150 clinical sites in over 25 countries. A futility analysis is planned for the first quarter of 2026, with completion of patient enrolment targeted for the third quarter of 2026.
Immutep Limited reported a busy quarter highlighted by a major licensing deal and solid cash reserves. The company’s subsidiary signed a strategic collaboration and exclusive license with Dr. Reddy’s for its lead cancer drug eftilagimod alfa (efti) in markets outside North America, Europe, Japan and Greater China, bringing a
Immutep advanced multiple trials, including the Phase III TACTI-004 lung cancer study, which had enrolled 289 of 756 patients and completed requirements for a futility analysis planned for Q1 CY2026. Positive data were also reported from the INSIGHT-003 lung, EFTISARC-NEO soft tissue sarcoma, and AIPAC-003 breast cancer studies, while a small urothelial cancer study was discontinued due to recruitment challenges. First-in-human Phase I data for autoimmune candidate IMP761 showed encouraging safety and pharmacodynamic signals.
Financially, Immutep ended 31 December 2025 with about
Immutep Limited furnishes a Form 6-K that includes an exhibit titled “Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study.” This indicates the company is providing investors with a positive clinical update on IMP761, which it describes as a first-in-class LAG-3 agonist antibody being studied for autoimmune diseases in a Phase I trial. The detailed results and implications of this Phase I study are contained in the attached exhibit, which is referenced but not reproduced here.
Immutep Limited submitted a Form 6-K to provide investors with an accompanying report on its clinical development activities. The filing mainly serves as a cover document for an exhibit rather than a detailed operational or financial update.
The attached exhibit, titled “Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace,” signals that the company is highlighting progress and ongoing patient enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial.
Immutep Limited, an Australia-based biotechnology company, has filed a report indicating it will present new data from its AIPAC-003 Phase II study at the 2025 San Antonio Breast Cancer Symposium. This presentation highlights ongoing clinical development work in breast cancer and suggests continued progress in evaluating its experimental therapy in this indication.
Immutep Limited furnished a Form 6-K noting it received an A$4.6 million research and development tax incentive from the French Government. This inflow reflects government support tied to the company’s R&D activities.
The update is administrative in nature but adds cash to the business, as disclosed in the exhibit titled “Immutep Receives A$4.6 million R&D Tax Incentive from French Government.”
Immutep Limited filed its annual report on Form 20-F, outlining ongoing development of LAG‑3 immunotherapies and continued operating losses. The company reported a net loss of A$61.4 million for the fiscal year ended June 30, 2025, compared with A$42.7 million in 2024. Shares outstanding were 1,460,389,575 as of June 30, 2025. Its ADSs, each representing 10 ordinary shares, trade on Nasdaq as IMMP.
Immutep has no products approved for sale and is focused on clinical candidates including eftilagimod alfa (efti), IMP761, and partnered programs such as IMP701 (ieramilimab) with Novartis. The company has collaboration and supply agreements with Merck & Co. for pembrolizumab combination trials (Phase II and Phase III) and with Merck KGaA/Pfizer for avelumab (Phase I), and a regional license with EOC Pharma in China.
Management expects further losses as clinical activities expand and notes reliance on third‑party manufacturers, trial enrollment challenges, regulatory risks, and the need for additional financing. Financial statements are prepared under IFRS and presented in Australian dollars.